Meeting
2019 ASCO Annual Meeting
Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.
Authors
William Bensinger
Fred Hutchinson Cancer Research Center, Seattle, WA
William Bensinger , Anastasios Raptis , James R. Berenson , Alexander I. Spira , Ajay K. Nooka , Maria Chaudhry , Peter van Zandvoort , Nitya Nair , Jeannette Lo , Jeroen Elassaiss-Schaap , Jackie Walling , Parameswaran Hari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03340883
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8012)
DOI
10.1200/JCO.2019.37.15_suppl.8012
Abstract #
8012
Poster Bd #
338
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
First Author: Andrzej J. Jakubowiak
Poster
2021 ASCO Annual Meeting
Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
First Author: Suzette Girgis
Poster
2019 ASCO Annual Meeting
Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.
First Author: Jeroen Elassaiss-Schaap
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess